4.2 Ectopic Pregnancy: Diagnosis & Management

Ectopic Pregnancy: Triage, Diagnostics & Management

Ectopic pregnancy occurs when a blastocyst implants outside the endometrial cavity of the uterus. It accounts for 1% to 2% of all pregnancies but causes 6% of all pregnancy-related maternal deaths, primarily due to catastrophic hemorrhage following tubal rupture.

Anatomic Sites and Risk Factors

• Anatomic Locations: Over 95% of ectopic pregnancies implant in the fallopian tube. Specific tubal distributions include the ampullary segment (70%, most common), isthmus (12%), fimbria (11%), and interstitial/cornual segment (2% to 3%). Interstitial ectopic pregnancies implant in the myometrial segment of the fallopian tube; rupture here occurs later (12–16 weeks) and results in massive, rapidly fatal hemorrhage due to the proximity of the uterine artery anastomosis.
• Major Risk Factors: Prior ectopic pregnancy (3- to 8-fold increased risk), history of salpingitis or pelvic inflammatory disease (PID), prior tubal reconstructive surgery or tubal sterilization, assisted reproductive technology (ART), current intrauterine device (IUD) in situ, and maternal tobacco smoking.

Diagnostic Algorithm: Quantitative hCG & Ultrasound Discriminatory Zone

The clinical triad of ectopic pregnancy comprises amenorrhea, vaginal bleeding, and unilateral pelvic pain. However, up to 50% of patients are asymptomatic or present with non-specific symptoms.

                  [ Hemodynamically Stable Early Pregnancy Bleeding/Pain ]
                                             │
                         Quantitative Serum β-hCG & TVUS
                                             │
              ┌──────────────────────────────┴──────────────────────────────┐
              ▼                                                             ▼
     [ β-hCG ≥ Discriminatory Zone ]                              [ β-hCG < Discriminatory Zone ]
     (1,500 – 2,000 mIU/mL)                                       (e.g., 500 mIU/mL)
              │                                                             │
       TVUS Findings:                                                TVUS Findings:
   ┌──────────┴──────────┐                                   ┌──────────────┴──────────────┐
   ▼                     ▼                                   ▼                             ▼
Intrauterine Sac    No Intrauterine Sac               Indeterminate (PUL)           Definite Ectopic
(Normal IUP)        (Ectopic Highly Presumed)         Serial β-hCG in 48h           Mass / Adnexal FHR
                         │                                   │                             │
                    Candidate for                     Expected Rise ≥35-53%        Candidate for MTX
                    Methotrexate vs                   If rises normally: IUP       vs Laparoscopy
                    Laparoscopy                       If plateaus/falls: Nonviable

• Transvaginal Ultrasound (TVUS) Discriminatory Zone: The discriminatory zone is the serum concentration of beta-hCG above which an intrauterine gestational sac must reliably be visualized on TVUS if a viable singleton intrauterine pregnancy is present. Most centers establish this threshold at 1,500 to 2,000 mIU/mL (or up to 3,500 mIU/mL to prevent misdiagnosis of viable IUPs). If the beta-hCG exceeds 2,000 mIU/mL and no intrauterine sac is visualized, ectopic pregnancy must be strongly suspected.
• Pregnancy of Unknown Location (PUL): When the beta-hCG is below the discriminatory zone and TVUS is indeterminate, serial quantitative beta-hCG levels are obtained 48 hours apart. A viable normal intrauterine pregnancy typically demonstrates an increase in beta-hCG of at least 35% to 53% over 48 hours. An abnormal, plateauing, or slow rise indicates an abnormal pregnancy (either nonviable intrauterine pregnancy or ectopic pregnancy).

Medical vs. Surgical Management Protocols

1. Methotrexate Medical Therapy

Methotrexate is a folic acid antagonist that competitively binds to dihydrofolate reductase, inhibiting DNA synthesis and cell proliferation in rapidly dividing trophoblastic tissue.

• Absolute Inclusion Criteria:
  • Hemodynamically stable with no signs of active intraperitoneal hemorrhage or rupture
  • Serum quantitative beta-hCG <5,000 mIU/mL (success rate >90%)
  • Transvaginal ultrasound demonstrates an adnexal mass <3.5 to 4.0 cm in greatest diameter
  • Absence of embryonic cardiac activity on ultrasound
  • Patient is willing and able to comply with extended post-treatment surveillance
  • Normal baseline liver transaminases, serum creatinine, and complete blood count
• Contraindications: Hemodynamic instability, renal impairment, active hepatic disease, pulmonary disease, active peptic ulcer disease, immunodeficiency, ongoing breastfeeding, or coexisting viable intrauterine pregnancy.
• Single-Dose Protocol: 50 mg/m² body surface area (BSA) IM on Day 1. Quantitative serum beta-hCG is measured on Day 4 and Day 7.
  • It is expected that hCG may rise between Day 1 and Day 4 as trophoblast cells undergo lysis.
  • A successful response is defined as a ≥15% decline in beta-hCG concentration between Day 4 and Day 7.
  • If beta-hCG declines by ≥15%, monitor beta-hCG weekly until undetectable (<5 mIU/mL).
  • If beta-hCG declines by <15% between Day 4 and Day 7, administer a second dose of methotrexate (50 mg/m² IM) on Day 7 or perform surgical laparoscopy.

2. Surgical Management

• Indications: Hemodynamic instability (tachycardia, hypotension, syncope), signs of tubal rupture or acute hemoperitoneum (peritoneal rebound, guarding, shoulder tip pain), failed medical therapy, adnexal mass ≥4 cm, or presence of fetal cardiac motion.
• Procedure: Laparoscopic salpingectomy (complete excision of the involved fallopian tube) is preferred over salpingostomy (linear incision over the tube and evacuation of products), as salpingectomy reduces the risk of persistent trophoblast tissue without significantly diminishing future fertility rates.

[!IMPORTANT] Which discriminatory-zone number should you use? Historic practice used 1,500–2,000 mIU/mL, and many local protocols still cite it. ACOG now advises a conservative threshold of 3,500 mIU/mL before concluding that a pregnancy of unknown location is not intrauterine, precisely because acting at the lower number has led to interruption of viable, desired intrauterine pregnancies. In a stable patient the safe practice is the same either way: repeat the quantitative hCG and the transvaginal scan rather than treat on a single value. Reserve immediate intervention for the unstable patient or for a definitive sonographic ectopic (extrauterine yolk sac, embryo, or cardiac activity).